Johri Atul Kumar, Paoletti Lawrence C, Glaser Philippe, Dua Meenakshi, Sharma Puja Kumari, Grandi Guido, Rappuoli Rino
School of Life Sciences, Jawaharlal Nehru University, New Delhi 110067, India.
Nat Rev Microbiol. 2006 Dec;4(12):932-42. doi: 10.1038/nrmicro1552. Epub 2006 Nov 6.
An ongoing public health challenge is to develop vaccines that are effective against infectious diseases that have global relevance. Vaccines against serotypes of group B Streptococcus (GBS) that are prevalent in the United States and Europe are not optimally efficacious against serotypes common to other parts of the world. New technologies and innovative approaches are being used to identify GBS antigens that overcome serotype-specificity and that could form the basis of a globally effective vaccine against this opportunistic pathogen. This Review highlights efforts towards this goal and describes a template that can be followed to develop vaccines against other bacterial pathogens.
一项持续存在的公共卫生挑战是研发出对具有全球影响的传染病有效的疫苗。针对在美国和欧洲流行的B族链球菌（GBS）血清型的疫苗，对世界其他地区常见的血清型的效果并不理想。新技术和创新方法正被用于识别GBS抗原，这些抗原可克服血清型特异性，并可能成为针对这种机会性病原体的全球有效疫苗的基础。本综述重点介绍了为实现这一目标所做的努力，并描述了一种可遵循的模板，用于研发针对其他细菌病原体的疫苗。
